Skip to main content

ScholarsBetaWeill Cornell Medicine

Browse About Sign in

Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research3

FiltersClear all

Status

Active, not recruiting1
Completed2

Study type

Interventional3
Not on ClinicalTrials.gov14

Phase

Phase 21
Phase 31
Not applicable1

Investigator

Anton Orlin1
Marc Joshua Dinkin1
Szilard Kiss1

Department

Ophthalmology3
Medicine750
Pediatrics81
Neurology46
Psychiatry46

Show all 22

Condition

Geographic Atrophy1
Macular Degeneration1
Pseudotumor Cerebri1
Retinopathy of Prematurity1

Intervention type

Drug2
Device1
Procedure1

Sponsor type

Industry3

Start date

to

Has results posted1

Interventional×Ophthalmology×Clear all

Showing 1–3 of 3 studiesSort:

Active, not recruitingInterventional · Not applicableNCT03556085 ↗
Clinical Evaluation of the Serenity River Stent System to Treat Idiopathic Intracranial Hypertension

Show fewer

Obstetrics and Gynecology41
Surgery40
Radiology36
Radiation Oncology28
Dermatology20
Neurological Surgery19
Cardiothoracic Surgery17
Urology15
Rehabilitation Medicine13
Population Health Sciences9
Otolaryngology Head and Neck Surgery7
Anesthesiology6
Emergency Medicine6
Orthopaedic Surgery6
Genetic Medicine2
Pathology and Laboratory Medicine1
Pharmacology1

Marc Joshua DinkinPI

Intervention: Device: Venous sinus stenting (Serenity River)
Dates: Aug 2018 – Oct 2022
Sponsor: Serenity Medical Inc.

Idiopathic Intracranial Hypertension

CompletedInterventional · Phase 2NCT03815825 ↗

A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Intervention: Drug: IONIS-FB-LRx · Drug: Placebo
Dates: Mar 2019 – Apr 2024
Sponsor: Ionis Pharmaceutical

Macular DegenerationGeographic Atrophy

CompletedInterventional · Phase 3NCT04101721 ↗

Randomized, Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity

Intervention: Drug: aflibercept · Procedure: laser photocoagulation
Dates: Oct 2019 – Aug 2022· Results posted
Sponsor: Regeneron Pharmaceuticals, Inc.

Retinopathy of Prematurity